Polyester-polyether temperature-sensitive gel with slow release of batimastat and preparation method thereof

Abstract

The invention relates to polyester-polyether temperature-sensitive gel with slow release of batimastat and a preparation method thereof. The polyester-polyether temperature-sensitive gel specificallyconsists of an amphipathy block copolymer, and medicines and a solvent of effective amounts, wherein the amphipathy block copolymer consists of polyethylene glycol as a hydrophilic block and polyesteras a lyophobic block in a ratio of 4wt%-40wt%; and the ratio of batimastat is 0.1wt%-10wt%. The gel preparation is capable of effectively slowly releasing batimastat for 1-6 weeks, is at a solution state at room temperature or lower, can be turned into a gel state at human body temperature, has syringeability, is capable of effectively inhibiting matrix metalloproteinase of tumor tissue togetherwith chemotherapeutic medicines through intratumoral or peritumoral injection or postoperative tumor cavity administration, and has the potential of preventing tumor cell migration.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a temperature-sensitive hydrogel capable of slow-release batimastat and a preparation method thereof. Background technique [0002] The development of new drug carrier materials is an important research direction of materials science, and it is also an important means to promote tumor treatment. In the current basic research in this field, most of the work aims to inhibit the growth of tumor tissue and make solid tumors shrink or even disappear, and has achieved many exciting results. Therefore, a pharmaceutical preparation that can effectively inhibit tumor metastasis has important research significance. [0003] At present, a variety of chemotherapeutic drugs have been used clinically, such as paclitaxel, cisplatin, doxorubicin, etc. These traditional anti-tumor drugs play an important role in cancer treatment, but almost all of these drugs kill tumor cells and i...

AI Technical Summary

Problems solved by technology

In addition, batimastat itself is almost insoluble in water, and its oral bioavailability is extremely poor. Therefore, intraperitoneal or thoracic injection is the only way for batimastat administration, and continuous administration (at least 3 weeks) is often required to maintain the effective drug in the body. Drug concentration will undoubtedly bring a lot of inconvenience to the treatment

It is for these reasons that there are currently no MMP inhibitors that target matrix metalloproteinases on the market, so a batimastat sustained-release preparation that can be injected in situ at the tumor site has practical application value

Images